Lee's Pharma Gains China Rights to Liver Cancer Drug from Tragara

Lee's Pharma has in-licensed Greater China and Southeast Asia rights to a potential liver cancer treatment from Tragara Pharma of San Diego. The drug is Tragara's oral multi-kinase inhibitor, TG02, which is currently in Phase Ib trials in the US. Lee's participated in Tragara's $13 million capital raise and made an upfront payment. Tragara is eligible for milestones and tiered royalties on future sales, while Lee’s will be responsible for all development and commercialization costs. More details.... Stock Symbol: (HK: 950) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.